Members of the SIGMA Consortium have extensive experience in collaborating in several multi-country studies under the principles of the European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP). All members are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. Past and current examples of collaborative experience are highlighted below. All studies are registered in the EU PAS register, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies (See Table ‘European Collaborations‘).
Each SIGMA member has access to different data, as summarized in the Table below.
The SIGMA consortium was presented virtually at ISPE’s 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2021 All Access) held August 23-25 2021.
|Full Title & EUPAS Link||Funding entity||Coord. Center||Other Participating SIGMA Members||Start Year|
|Cilostazol Drug Utilisation Study||Otsuka Pharmaceutical Europe, Ltd.||RTI-HS, BIPS, IDIAPJGol||2013|
|Safety Evaluation of Adverse Reactions in Diabetes - Comparative studies||European Commission||BIPS, PHARMO, RTI-HS||2011|
Patterns and Determinants of Use of Oral Contraceptives in the European Union
|European Medicines Agency (EMA)||ARS Toscana, PHARMO||2011|
|CAncer Risk and INsulin analoGues (CARING)||European Commission||Utrecht U., Aarhus U., NIPH||2011|
|Study of Acute Liver Transplant: A study of NSAIDs-exposed acute liver failure in European transplant centres||Helsinn Healthcare S.A.||BPE, RTI-HS||2008|